Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, Max-Planck Union Aims for Affordable Large-Scale Genetic-Variability Studies

NEW YORK, Feb. 7 - Transgenomic on Thursday said that it has begun a partnership with the Max-Planck Institute for Molecular Genetics to develop a high-throughput system to discover genetic variation.

 

The partners hope that their multiyear collaboration, funded by the German National Genome Research Network, will create a system that will permit large-scale studies of genetic variability at a reasonable cost.

 

The research will be conducted in the labs of Max Planck's Hans Lehrach, who heads the institute's department of vertebrate genomics. That group, which is involved in a comprehensive project to isolate and identify the genes of the vertebrate genome, now focuses on model organism genomes as well as human chromosomes X and 21, and the genetics of Huntington's chorea.

 

Transgenomic, based in Omaha, Neb., develops and sells DNA and RNA analysis instruments. Its Wave system identifies DNA mutations using micro-beads and a DNA separation column.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.